Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- University of Nebraska
- Registration Number
- NCT00004112
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00003944
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
- Conditions
- LeukemiaLymphomaOral Complications
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 111
- Registration Number
- NCT00004061
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors
- Conditions
- NeuroblastomaBrain and Central Nervous System Tumors
- Interventions
- Biological: filgrastimDrug: carboplatinDrug: cyclophosphamideDrug: thiotepaDrug: vincristine sulfateProcedure: bone marrow ablation with stem cell supportProcedure: peripheral blood stem cell transplantationRadiation: radiation therapy
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 25
- Registration Number
- NCT00003846
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Biological Therapy in Treating Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- St. Luke's Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00002780
- Locations
- 🇺🇸
St. Luke's Medical Center, Milwaukee, Wisconsin, United States
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma
- Conditions
- LymphomaMultiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00002552
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
- Conditions
- LeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 280
- Registration Number
- NCT00002547
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: bleomycin sulfateBiological: filgrastimDrug: cyclophosphamideDrug: cytarabineDrug: doxorubicin hydrochlorideDrug: etoposideDrug: leucovorin calciumDrug: methotrexateDrug: prednisoneDrug: trimethoprim-sulfamethoxazoleDrug: vincristine sulfateRadiation: radiation therapyDrug: Intrathecal cytarabine
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 52
- Registration Number
- NCT00002571
- Locations
- 🇺🇸
MBCCOP - University of South Alabama, Mobile, Alabama, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Cancer Research Campaign Clinical Trials Centre
- Target Recruit Count
- 200
- Registration Number
- NCT00002576
- Locations
- 🇬🇧
Nottingham City Hospital NHS Trust, Nottingham, England, United Kingdom
Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma
- Conditions
- Central Nervous System TumorsBrain Tumors
- Interventions
- Biological: filgrastimDrug: cisplatinDrug: cyclophosphamideDrug: lomustineDrug: mesnaDrug: vincristine sulfateRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 421
- Registration Number
- NCT00002875
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.